



Dynavax to Present at Deutsche Bank Securities 31st Annual Healthcare Conference

BERKELEY, Calif., April 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that Dino Dina, MD, President and CEO, will present an overview of the company at the Deutsche Bank Securities 31st Annual Healthcare conference, May 3, 2006 at 2:30 p.m. Eastern, in Boston. The webcast presentation may be accessed by visiting http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DVAX&item_id=1209122.

The presentation may also be accessed by visiting the Dynavax website at <http://www.Dynavax.com> under the Investors section where it will also be archived for 30 days following the presentation.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, that has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; SUPERVAX, a two-dose hepatitis B vaccine; an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial; a cancer therapy currently in a Phase 2 clinical trial for non-Hodgkins lymphoma and in preclinical development in solid tumors; and preclinical programs in hepatitis B and hepatitis C therapy.

SOURCE Dynavax Technologies Corporation

04/25/2006

CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com

Web site: <http://www.dynavax.com>

(DVAX)

04/25/2006 16:08 EDT <http://www.prnewswire.com>